

5 What is claimed is:

1. A three-dimensional model selected from the group consisting of: (a) a three-dimensional model of a human IgE Fc region comprising Cε3 and Cε4 domains (Fc-Cε3/Cε4), wherein said model substantially represents the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3;
10 and (b) a three-dimensional model comprising a modification of said model of (a), wherein said modification represents an antibody Fc region that binds to a FcεRIα protein.
2. A method to produce the three-dimensional model of Claim 1, wherein the three-dimensional model represents the Fc-Cε3/Cε4 region of a human IgE antibody, said
15 method comprising representing amino acids of said region at substantially the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3.
3. A method to produce a three-dimensional model of a FcεRIα binding domain other than a human FcεRIα binding domain represented by the three-dimensional
20 model substantially representing the atomic coordinates specified in Claim 1, said method comprising homology modeling.

FOR Filing ONLY

- 5 4. An isolated crystal of a Fc-C ϵ 3/C ϵ 4 region of a human IgE antibody.
5. A method to produce the isolated crystal of Claim 4, said method
comprising vapor diffusion.

Approved for Release

- 5 6. An isolated Fc-C ϵ 3/C ϵ 4 protein selected from the group consisting of: (a)
a protein consisting of SEQ ID NO:2; and (b) a homologous protein that is structurally
homologous to a protein of (a), wherein said homologous protein binds to a Fc ϵ RI α
protein.
7. A nucleic acid molecule comprising a nucleic acid sequence that encodes
10 said isolated Fc-C ϵ 3/C ϵ 4 protein of Claim 6.
8. A recombinant molecule comprising the nucleic acid sequence of Claim 7.
9. A recombinant virus comprising the nucleic acid sequence of Claim 7.
10. A recombinant cell comprising the nucleic acid sequence of Claim 7.
11. A method to produce a protein comprising culturing the recombinant cell
15 of Claim 10.

- 5 12. A method to identify a compound that inhibits the binding between an IgE antibody and a FcεRIα protein, said method comprising using a three-dimensional model of a Fc-Cε3/Cε4 region of a human IgE to identify said compound, wherein said model substantially represents the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3.
- 10 13. An inhibitory compound identified in accordance with the method of Claim 12.
14. A therapeutic composition comprising the inhibitory compound of Claim 13.
15. A method to protect an animal from allergy, said method comprising
- 15 administering to said animal the inhibitory compound of Claim 13.

5 16. A method to improve a function of an antibody comprising a Fc-C ϵ 3/C ϵ 4 region, said improved function being selected from the group consisting of increased stability, increased affinity for an IgE binding domain of a Fc ϵ RI α protein, altered substrate specificity, and increased solubility, said method comprising:

10 (a) analyzing a three-dimensional model substantially representing the atomic coordinates specified in a Table selected from the group consisting of Table 1, Table 2 and Table 3 to identify at least one amino acid of the Fc-C ϵ 3/C ϵ 4 region represented by said model which if replaced by said identified amino acid(s) improves at least one of said functions of said Fc-C ϵ 3/C ϵ 4 region; and

15 (b) replacing said identified amino acid(s) to produce a mutein having at least one of said improved functions.

20 17. A mutein produced by the method of Claim 16, wherein said mutein has an improved function compared to a Fc-C ϵ 3/C ϵ 4 protein comprising amino acid sequence SEQ ID NO:2, wherein said improved function is selected from the group consisting of increased stability compared to the stability of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2, increased affinity for a Fc ϵ RI α protein compared to the Fc ϵ RI α affinity of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2, altered substrate affinity compared to the affinity for human Fc ϵ RI α of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2, and increased solubility compared to the solubility of a human IgE Fc region comprising amino acid sequence SEQ ID NO:2.

10 19. The polypeptide of Claim 18, wherein said composition is selected from
the group consisting of a linker between Cε2 and Cε3, a BC loop of Cε3, a DE loop of
Cε3, and a FG loop of Cε3, a loop or strand defining the interdomain groove, a AB helix
of Cε3 and, a region lying above said AB helix of Cε3.

-296-